These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 33994737)

  • 41. Immunotherapy of pancreatic cancer.
    Sunami Y; Kleeff J
    Prog Mol Biol Transl Sci; 2019; 164():189-216. PubMed ID: 31383405
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Perspectives in the treatment of pancreatic adenocarcinoma.
    Cid-Arregui A; Juarez V
    World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devastating cancer?
    Sereti E; Karagianellou T; Kotsoni I; Magouliotis D; Kamposioras K; Ulukaya E; Sakellaridis N; Zacharoulis D; Dimas K
    J Proteomics; 2018 Sep; 188():107-118. PubMed ID: 29398619
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy.
    Zhu L; Staley C; Kooby D; El-Rays B; Mao H; Yang L
    Cancer Lett; 2017 Mar; 388():139-148. PubMed ID: 27916607
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions.
    Herting CJ; Karpovsky I; Lesinski GB
    Cancer Metastasis Rev; 2021 Sep; 40(3):675-689. PubMed ID: 34591240
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies.
    Pham TND; Shields MA; Spaulding C; Principe DR; Li B; Underwood PW; Trevino JG; Bentrem DJ; Munshi HG
    Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33503832
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects.
    Nsingwane Z; Candy G; Devar J; Omoshoro-Jones J; Smith M; Nweke E
    Mol Biol Rep; 2020 Aug; 47(8):6269-6280. PubMed ID: 32661873
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Uncovering key targets of success for immunotherapy in pancreatic cancer.
    Pretta A; Lai E; Persano M; Donisi C; Pinna G; Cimbro E; Parrino A; Spanu D; Mariani S; Liscia N; Dubois M; Migliari M; Impera V; Saba G; Pusceddu V; Puzzoni M; Ziranu P; Scartozzi M
    Expert Opin Ther Targets; 2021 Nov; 25(11):987-1005. PubMed ID: 34806517
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Unsupervised subtyping and methylation landscape of pancreatic ductal adenocarcinoma.
    Roy S; Singh AP; Gupta D
    Heliyon; 2021 Jan; 7(1):e06000. PubMed ID: 33521362
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials.
    Paliard X; Rixe O
    Target Oncol; 2019 Dec; 14(6):631-637. PubMed ID: 31595386
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Apoptosis in the Pancreatic Cancer Tumor Microenvironment-The Double-Edged Sword of Cancer-Associated Fibroblasts.
    Pfeifer E; Burchell JM; Dazzi F; Sarker D; Beatson R
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359823
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective.
    Perales-Patón J; Piñeiro-Yañez E; Tejero H; López-Casas PP; Hidalgo M; Gómez-López G; Al-Shahrour F
    Public Health Genomics; 2017; 20(2):81-91. PubMed ID: 28858862
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer.
    Sadozai H; Acharjee A; Eppenberger-Castori S; Gloor B; Gruber T; Schenk M; Karamitopoulou E
    Front Immunol; 2021; 12():643529. PubMed ID: 33679807
    [No Abstract]   [Full Text] [Related]  

  • 55. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
    Panchal K; Sahoo RK; Gupta U; Chaurasiya A
    Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).
    Golan T; Milella M; Ackerstein A; Berger R
    J Exp Clin Cancer Res; 2017 Dec; 36(1):192. PubMed ID: 29282151
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.
    Tesfaye AA; Kamgar M; Azmi A; Philip PA
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):131-148. PubMed ID: 29254387
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PDAC as an Immune Evasive Disease: Can 3D Model Systems Aid to Tackle This Clinical Problem?
    Narayanan S; Vicent S; Ponz-Sarvisé M
    Front Cell Dev Biol; 2021; 9():787249. PubMed ID: 34957115
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Complex HuR function in pancreatic cancer cells.
    Brody JR; Dixon DA
    Wiley Interdiscip Rev RNA; 2018 May; 9(3):e1469. PubMed ID: 29452455
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent advances in precision medicine for pancreatic ductal adenocarcinoma.
    Hayashi H; Higashi T; Miyata T; Yamashita YI; Baba H
    Ann Gastroenterol Surg; 2021 Jul; 5(4):457-466. PubMed ID: 34337294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.